Tratamiento del hirsutismo con espironolactona y con espironolactona más dexametasona

Background: Spironolactone has an anti androgenic effect, inhibiting the binding of androgens to their receptor. This antagonistic effect is the basis for the use of spironolactone in the treatment of hirsutism. Aim: To study the effectiveness and safety of spironolactone in the treatment of hirsute...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Devoto C,Enzo, Aravena C,Lucía, Ríos S,Rafael
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2000
Materias:	Dexamethasone Hirsutism Hyperandrogenism spironolactone
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872000000800006
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872000000800006
record_format	dspace
spelling	oai:scielo:S0034-988720000008000062005-11-29Tratamiento del hirsutismo con espironolactona y con espironolactona más dexametasonaDevoto C,EnzoAravena C,LucíaRíos S,Rafael Dexamethasone Hirsutism Hyperandrogenism spironolactone Background: Spironolactone has an anti androgenic effect, inhibiting the binding of androgens to their receptor. This antagonistic effect is the basis for the use of spironolactone in the treatment of hirsutism. Aim: To study the effectiveness and safety of spironolactone in the treatment of hirsute women and of the association of spironolactone plus dexamethasone in the treatment of hirsutism with glucocorticoid sensitive hyperandrogenism. Patients and method: Sixteen women (group 1) with peripheral hirsutism (defined as those with normal androgens levels, normal menstrual cycles and ovulation) and 24 women (group 2) with glucocorticoid sensitive hyperandrogenic hirsutism were studied. Group 1 was treated with spironolactone 50 mg bid and group 2 with same spironolactone dose plus dexamethasone 0.5 mg at 23 h during one month and 0.25 mg thereafter. Patients were followed during one year. Results: After one year of treatment, a 54% reduction in Moncada hirsutism escore was observed in group 1 and 52% reduction in group 2. Observed secondary effects of spironolactone were increases in diuresis, fatigability, acne aggravation and seborrhea in two patients. Two additional patients had spotting. No secondary effect attributable to glucocorticoid use were observed. Conclusions: Spironolactone is effective and safe in the treatment of hirsutism. Androgenic supression did no increases its effectiveness, underscoring the peripheral anti androgenic activity os spironolactone. (Rev Méd Chile 2000; 128: 868-75).info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.128 n.8 20002000-08-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872000000800006es10.4067/S0034-98872000000800006
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Dexamethasone Hirsutism Hyperandrogenism spironolactone
spellingShingle	Dexamethasone Hirsutism Hyperandrogenism spironolactone Devoto C,Enzo Aravena C,Lucía Ríos S,Rafael Tratamiento del hirsutismo con espironolactona y con espironolactona más dexametasona
description	Background: Spironolactone has an anti androgenic effect, inhibiting the binding of androgens to their receptor. This antagonistic effect is the basis for the use of spironolactone in the treatment of hirsutism. Aim: To study the effectiveness and safety of spironolactone in the treatment of hirsute women and of the association of spironolactone plus dexamethasone in the treatment of hirsutism with glucocorticoid sensitive hyperandrogenism. Patients and method: Sixteen women (group 1) with peripheral hirsutism (defined as those with normal androgens levels, normal menstrual cycles and ovulation) and 24 women (group 2) with glucocorticoid sensitive hyperandrogenic hirsutism were studied. Group 1 was treated with spironolactone 50 mg bid and group 2 with same spironolactone dose plus dexamethasone 0.5 mg at 23 h during one month and 0.25 mg thereafter. Patients were followed during one year. Results: After one year of treatment, a 54% reduction in Moncada hirsutism escore was observed in group 1 and 52% reduction in group 2. Observed secondary effects of spironolactone were increases in diuresis, fatigability, acne aggravation and seborrhea in two patients. Two additional patients had spotting. No secondary effect attributable to glucocorticoid use were observed. Conclusions: Spironolactone is effective and safe in the treatment of hirsutism. Androgenic supression did no increases its effectiveness, underscoring the peripheral anti androgenic activity os spironolactone. (Rev Méd Chile 2000; 128: 868-75).
author	Devoto C,Enzo Aravena C,Lucía Ríos S,Rafael
author_facet	Devoto C,Enzo Aravena C,Lucía Ríos S,Rafael
author_sort	Devoto C,Enzo
title	Tratamiento del hirsutismo con espironolactona y con espironolactona más dexametasona
title_short	Tratamiento del hirsutismo con espironolactona y con espironolactona más dexametasona
title_full	Tratamiento del hirsutismo con espironolactona y con espironolactona más dexametasona
title_fullStr	Tratamiento del hirsutismo con espironolactona y con espironolactona más dexametasona
title_full_unstemmed	Tratamiento del hirsutismo con espironolactona y con espironolactona más dexametasona
title_sort	tratamiento del hirsutismo con espironolactona y con espironolactona más dexametasona
publisher	Sociedad Médica de Santiago
publishDate	2000
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872000000800006
work_keys_str_mv	AT devotocenzo tratamientodelhirsutismoconespironolactonayconespironolactonamasdexametasona AT aravenaclucia tratamientodelhirsutismoconespironolactonayconespironolactonamasdexametasona AT riossrafael tratamientodelhirsutismoconespironolactonayconespironolactonamasdexametasona
_version_	1718435931332018176

Tratamiento del hirsutismo con espironolactona y con espironolactona más dexametasona

Ejemplares similares